Pharvaris is thrilled to announce a significant milestone in its mission to revolutionize the treatment of hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company has successfully raised $200 million in a recent funding round, marking a transformative moment in the advancement of its innovative pipeline. As a clinical-stage organization, Pharvaris is steadfast in its commitment to developing novel small molecule oral bradykinin-B2-receptor antagonists, aiming to replace traditional injected therapies with more patient-friendly alternatives. This fresh influx of capital is poised to accelerate the progression of Pharvaris’s clinical programs, which are designed to address the considerable unmet medical needs in their therapeutic areas.
At the heart of Pharvaris’s innovation is a team with deep expertise in pharmaceutical development and rare disorders. Notably, the company reunites the pioneering core team responsible for the discovery and approval of icatibant, a milestone achievement in the treatment of HAE. This seasoned team’s reassembly brings invaluable insights and proven expertise to the design and development of next-generation therapeutics that promise to improve patient outcomes. The raised funds will support continued preclinical research and the advancement into critical clinical trial phases, setting the stage for a broader exploration of safety, efficacy, and dosing strategies in patients.
With its strategic focus on oral therapies and its robust scientific foundation, Pharvaris is well-positioned to make a significant impact in the treatment landscape. This successful funding round not only underscores investor confidence in the company’s vision and strategy but also reinforces the promise of a future where patients can benefit from innovative, more accessible treatment options.
